Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021;153(1 & 2):93-114.
doi: 10.4103/ijmr.IJMR_4431_20.

Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates

Labanya Mukhopadhyay  1 , Pragya D Yadav  2 , Nivedita Gupta  1 , Sreelekshmy Mohandas  2 , Deepak Y Patil  2 , Anita Shete-Aich  2 , Samiran Panda  3 , Balram Bhargava  4
Affiliations

Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates

Labanya Mukhopadhyay et al. Indian J Med Res. 2021.

Abstract

Background & objectives: The COVID-19 pandemic has emerged as a global public health crisis and research groups worldwide are engaged in developing vaccine candidates to curb its transmission, with a few vaccines having progressed to advanced stages of clinical trials. The aim of this systematic review was to compare immunogenicity and protective efficacy of various SARS-CoV-2 vaccine candidates tested in non-human primate (NHP) models.

Methods: Literature on effect of SARS-CoV-2 vaccines in NHP models reported on PubMed and preprint platforms (medRxiv and bioRxiv) till October 22, 2020, was searched with the following terms: coronavirus vaccine, COVID-19 vaccine, SARS-CoV-2 vaccine, nonhuman primate, and rhesus macaque.

Results: Our search yielded 19 studies, which reported immune response elicited by 18 vaccine candidates in NHP. All the vaccines induced detectable neutralizing antibody (NAb) titres in the serum of vaccinated animals, with some showing effective viral clearance from various organs. The vaccinated animals also showed nil to mild histopathological changes in their lungs compared to placebo groups in the trials that performed necropsy.

Interpretation & conclusions: Our findings highlighted onset of quick immunogenicity and protective efficacy of mRNA-1273, followed by Ad26.CoV2.S, NVX-CoV2373, BNT162b2, RBD and BBV152 vaccine candidates in preclinical trials as compared to the others. NHP data also showed correlation with clinical trial data available for a few vaccines. Preclinical trials of COVID-19 vaccine candidates in NHPs yielded promising results, with some candidates faring better than others.

Keywords: COVID-19; T-cell response; immune response; inactivated vaccine; neutralizing antibody; non-human primate; protein subunit vaccine; vaccine; viral clearance.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure
Figure
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart depicting study design.
See this image and copyright information in PMC

Comment in

References

    1. WHO COVID-19. Draft landscape of COVID-19 candidate vaccines. WHO; 2020. [accessed on October 29, 2020]. p. 3. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-cand... .
    1. Dinda AK, Tripathi SK, John B. Revisiting regulatory framework in India for accelerated vaccine development in pandemics with an evidence-based fast-tracking strategy. Indian J Med Res. 2020;152:156–63. - PMC - PubMed
    1. Bregu M, Draper SJ, Hill AV, Greenwood BM. Accelerating vaccine development and deployment: Report of a Royal Society Satellite Meeting. Philos Trans R Soc Lond B Biol Sci. 2011;366:2841–9. - PMC - PubMed
    1. Randolph HE, Barreiro LB. Herd immunity: Understanding COVID-19. Immunity. 2020;52:737–41. - PMC - PubMed
    1. Adalja AA, Watson M, Cicero A, Inglesby T. Vaccine platforms: State of the field and looming challenges. 2019. [accessed on October 12, 2020]. Available from: http://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2... .

Publication types